How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease
During the American Association of Cancer Research (AACR) Virtual Annual Meeting I, the AML Hub was pleased to speak to Christine Spencer, Parker Institute for Cancer Immunotherapy, San-Francisco, US ...
24 Kesä 202024min
Can CD47 antibody therapy be safely used for AML and MDS?
During the 25th Congress of the European Hematology Association (EHA), the AML Hub hosted a discussion between David Sallman, Moffitt Cancer Center, Tampa, US, and Steering Committee Member Naval Dave...
22 Kesä 202014min
How does the type of prior treatment affect the risk of therapy-related myeloid neoplasms?
During the American Society of Clinical Oncology (ASCO) Annual Meeting, Alexander Maurer from the AML Hub hosted a group discussion with Michael Ozga and Caner Saygin, both from The Ohio State Univers...
9 Kesä 202020min
